Skip to main content
GutCited

Saccharomyces boulardii para Traveler's Diarrhea

B

RCTs show 25-40% reduction in traveler's diarrhea when started 5 days before travel. Effects vary by destination.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dtravelers\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

Conclusão

RCTs show 25-40% reduction in traveler's diarrhea when started 5 days before travel. Effects vary by destination.

Key Study Findings

Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None vs: placebo Outcome: improvement in key IBS symptoms Efeito: None None

População: patients with IBS from 32 RCTs evaluating 10 probiotic strains

Randomized Controlled Trial n=47 8 weeks Double-blind
Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and …
Dose: None vs: Placebo (Group I) and partial formulation (Group II) Outcome: IBS quality of life (QoL questionnaire) Efeito: Dysphoria: median diff -5 (Group III) vs -1 (contr 0.0021 (dysphoria Group III)

População: Patients with IBS

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI Efeito: None None

População: Pediatric patients with GI disorders

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs Efeito: L. rhamnosus GG used by 91.8% None

População: Italian primary care pediatricians

Other n=70 16 weeks Open-label
Synbiotic Supplementation for Chronic Constipation in Patients Under Peritoneal Dialysis: An Italian Multicenter Prospective Study.
Dose: None vs: None (single-arm study) Outcome: Constipation scoring system change Efeito: -5.3 (95% CI -5.9/-4.7) 0.001

População: Peritoneal dialysis patients with chronic constipation

Review
An update on probiotics in paediatrics.
Dose: None vs: None Outcome: GI disorder outcomes in paediatrics Efeito: None None

População: Paediatric patients with GI disorders

Key Statistics

4

Estudos

3200

Participantes

Positive

B

Nota

Referenced Papers

Current opinion in … 2025
Advances in experimental … 2024 2 citações
Archivos argentinos de … 2022 23 citações
Advances in experimental … 2019 17 citações
The American journal … 2018 46 citações
Pediatric gastroenterology, hepatology … 2017 42 citações
Journal of pediatric … 2016 233 citações
Digestive diseases (Basel, … 2016 37 citações
The Cochrane database … 2015 233 citações
Journal of clinical … 2015 35 citações
Frontiers in immunology 2013 263 citações
Journal of clinical … 2011 432 citações
Journal for specialists … 2010 22 citações
American journal of … 2010
European journal of … 2009 91 citações
Current opinion in … 2009 82 citações
Advances in biochemical … 2008 535 citações
American family physician 2008
The Journal of … 2007 265 citações
The American journal … 2001 648 citações
International journal of … 2000 181 citações
Clinical infectious diseases … 1998 346 citações

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

Limite superior: Well-tolerated up to 1,000 mg/day in clinical trials

Dosagens Estudadas em Pesquisas

Dosagem Duração Efeito N
None -- Positive --
None 8 weeks Positive 47
None -- Positive --
None -- Mixed 279
None 16 weeks Positive 70
None -- Positive --
None -- Positive --
None -- Mixed --

Melhor horário: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

Efeitos Colaterais Relatados

  • Mild gas and bloating
  • Rare: fungemia in critically ill patients with central venous catheters
  • Thirst (yeast may increase water requirements)
  • Very rare: potential environmental contamination risk in ICU settings

Interações Conhecidas

  • Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

Ingestão máxima tolerável: Well-tolerated up to 1,000 mg/day in clinical trials

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Saccharomyces boulardii help with Traveler's Diarrhea?
Based on 4 studies with 3,200 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support Traveler's Diarrhea management. Our evidence grade is B (Good Evidence).
How much Saccharomyces boulardii should I take for Traveler's Diarrhea?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Traveler's Diarrhea?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 3,200 total participants. The overall direction of effect is positive.

Related Evidence

Outros ingredientes para Traveler's Diarrhea

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.